Related Experiment Video
Updated: Jun 20, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
Therapeutic potential of cannabidiol in depression
Matti Bock Guldager1, Adriano Maia Chaves Filho2, Caroline Biojone1
1Department of Biomedicine, Health Faculty, Aarhus University, Aarhus, Denmark; Translational Neuropsychiatry Unit (TNU), Department of Clinical Medicine, Health Faculty, Aarhus University, Aarhus, Denmark.
Abstract:
Major depressive disorder (MDD) is a widespread and debilitating condition affecting a significant portion of the global population. Traditional treatment for MDD has primarily involved drugs that increase brain monoamines by inhibiting their uptake or metabolism, which is the basis for the monoaminergic hypothesis of depression. However, these treatments are only partially effective, with many patients experiencing delayed responses, residual symptoms, or complete non-response, rendering the current view of the hypothesis as reductionist. Cannabidiol (CBD) has shown promising results in preclinical models and human studies. Its mechanism is not well-understood, but may involve monoamine and endocannabinoid signaling, control of neuroinflammation and enhanced neuroplasticity. This chapter will explore CBD's effects in preclinical and clinical studies, its molecular mechanisms, and its potential as a treatment for MDD.
More Related Videos
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Therapy
Antianxiety Medications
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Antidepressant Drugs: MAOIs and Other Agents
G-protein Coupled Receptors
Depression: Overview

